利妥昔单抗在难治性重症肌无力中的研究进展

摘要

重症肌无力是一种自身免疫性疾病,自身抗体影响神经肌肉接头突触后膜成分,导致神经肌肉传递障碍.多数患者经治疗可获得良好的临床改善,部分难治性重症肌无力患者经治疗不能达到临床缓解,或者免疫抑制剂的不良反应明显导致应用受限.利妥昔单抗为一种人鼠嵌合抗体,可结合B细胞表面的CD20抗原,有文献报道利妥昔单抗在治疗难治性重症肌无力中有效.该文主要讨论利妥昔单抗在难治性重症肌无力中的研究进展.%Myasthenia gravis is an autoimmune disorder of the neuromuscular junction caused by circu-lating antibodies specific for the post-synaptic receptor. It results in neuromuscular transmission disorders. After optimal treatment with standard drugs,most myasthenia gravis patients can achieve a good life quality. Part of patients cannot get stable clinical remission or minimal manifestation with standard therapy. Rituximab is a chim-eric mouse/human antibody specific for the CD20 B-cell surface antigen. Studies have showed that rituximab is effective in the refractory myasthenia gravis. This review mainly discusses about the advances of rituximab in the treatment of refractory myasthenia gravis.